Navigation Links
Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for Pixuvri®
Date:11/1/2010

SEATTLE, Nov. 1, 2010 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that it has submitted a Marketing Authorization Application ("MAA") to the European Medicines Agency ("EMA") for Pixuvri® (pixantrone dimaleate) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL"). The application submission follows a positive opinion from the EMA's Pediatric Committee (the "PDCO"), where PDCO agreed to CTI's Pediatric Investigation Plan ("PIP") for Pixuvri.

"This is an important milestone for CTI, and underscores our commitment to making pixantrone available to patients who currently have no approved or effective therapies for this life threatening disease," said James A. Bianco, M.D., CEO of CTI. "We appreciate the efforts of all the people who made the MAA submission possible, especially the investigators and patients who participated in our clinical trial."  

"PIX301 was not only the first and only randomized trial in this patient population, it was also the largest study ever conducted for patients with multiply relapsed and refractory aggressive NHL. The positive results of this trial are among the most effective ever reported in this group of patients," noted Ruth Pettengell, M.D., of St. George's Hospital, University of London, the principal investigator on the study. "The robustness of the drug's effect in prolonging progression free survival irrespective of risk factors lends to the strength and credibility of the clinical benefit provided to patients in the trial. Currently there are no approved drugs available to patients today as such pixantrone will be a valuable new addition to offer these patients a new hope for controlling their disease."

Pixantrone was granted orphan drug status by the EMA for the treatment of diffuse large B-cell lymphoma (DLBCL). CTI expects that the EMA will make a determination regarding the ac
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
9. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
10. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
11. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 2014 Research and ... of the  "Global Operating Room Equipment Market ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,An operating room ... in a healthcare facility used to perform ... advanced equipment, which ensures patient care and ...
(Date:8/22/2014)... , Aug. 22, 2014 /CNW/ - On Aug. ... , the Canadian Medical Association (CMA) voted on ... any plant material, including medicinal cannabis. Bedrocan Cannabis Corp., ... supportive of the CMA motion. The CMA ... particular hazards associated with smoking any plant material, including ...
(Date:8/22/2014)... Research and Markets has announced ... Catheter Industry Report 2014" report to their offering. ... Industry Report 2014 is a professional and in-depth study ... industry with a focus on the Chinese situation. ... including definitions, classifications, applications and industry chain structure. The ...
Breaking Medicine Technology:Global Operating Room Equipment Market 2014-2018: Key Vendors are Getinge, STERIS, Stykron and TRUMPF Medical Systems 2Bedrocan Canada Statement Regarding Canadian Medical Association Motion on Smoking Marijuana 2Global and Chinese Intravenous Catheter Industry Report 2014 2
... 2012  The United States Patent & Trademark Office (USPTO) ... BDSI ) that the USPTO has rejected all claims ... No. 7,357,891 (the ,891 Patent) which is currently being ... (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO ) ...
... Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) ... provide this corporate update detailing the Company,s business ... acquisition of its wholly owned subsidiary Healthcare Distribution ... sector.  The U.S. pharmaceutical distribution sector is approximately ...
Cached Medicine Technology:US Patent Office Rejection of All Claims in Final Asserted MonoSol Patent Further Supports BioDelivery Sciences' Position 2US Patent Office Rejection of All Claims in Final Asserted MonoSol Patent Further Supports BioDelivery Sciences' Position 3Sunpeaks Ventures Enters $45 Billion Specialty Drug Distribution Sector 2Sunpeaks Ventures Enters $45 Billion Specialty Drug Distribution Sector 3
(Date:8/23/2014)... The MPWMD Board of Directors voted on Monday, ... sole source of water for commercial and industrial properties. ... Brown of Archworks, LLC in Carmel, California. , This ... a water district in the State of California has approved ... AWGs at this time can now be used as a ...
(Date:8/23/2014)... (PRWEB) August 23, 2014 Pixel Film Studios, ... announced today the release of ProIntro Vol.3, a customizable ... fresh and professional tile just by dragging ProIntro Vol.3 in ... "ProIntro Vol.3 is a definite time saver and i think ... pack with 30 beautifully designed titles made with Final Cut ...
(Date:8/23/2014)... Dealing with a drug or alcohol substance abuse ... is a child. Adolescent addiction has been an important issue ... a new helpline is now providing a valuable resource for ... a real addiction recovery center. , The Troubled Teens Atlanta ... the community. By calling (404) 975-2762, parents and their teens ...
(Date:8/23/2014)... Wilmington, NC (PRWEB) August 23, 2014 ... across North Carolina. It’s no different in Wilmington, NC. ... Young adults are falling victim to drug and alcohol ... young people are looking to overcome substance abuse, but ... Finding an adolescent treatment facility can be a challenge ...
(Date:8/23/2014)... 23, 2014 Summer vacation is almost over ... back in session. While shopping for school supplies and a ... Batzner encourages parents and students to also spend some time ... are excellent hitchhikers and thrive in heavily populated places,” said ... classrooms and dorms the perfect settings for bed bugs to ...
Breaking Medicine News(10 mins):Health News:Historical Moment in the Monterey Peninsula, Brings Drought Relief Solution to California, with the Help of EcoloBlue and AWG Technology 2Health News:A new plugin was announced today, ProIntro Vol.3 from Pixel Film Studios for Final Cut Pro X 2Health News:Atlanta’s New Troubled Teen Helpline Is Making a Difference in the Community 2Health News:Troubled Teens Wilmington Helpline Guides Adolescents to the Path of Recovery 2Health News:Expert Advice for a Bed Bug-Free School Year 2
... in the American Journal of Clinical Nutrition it was observed ... the build up of plaque in the arteries that can ... can protect against the formation of plaque in the arteries. ... diagnosed with heart disease or who had suffered a heart ...
... breakthrough discovery, American researchers have found some of the first ... womb. There have always been theories that unborn babies will ... read to or played music while still in the womb. ... been questionable in the past because there has been little ...
... on the vision loss with lazy eye, but not in the ... of vision loss in the normal eye in the future.// At ... called lazy eye. ,Many countries routinely screen for lazy ... possible in that eye. Some, but not all, countries place high ...
... who are given antibiotics after being hospitalized have a lower risk ... Researchers from Croydon Hospital, England //say that the reduced risk ... playing a role in heart disease. The effect was seen regardless ... Helicobacter pylori or Chlamydia pneumoniae. ...
... new survey observe that many people are still not very much ... cancers account for about 4% of all malignancies. //The warning signs ... to a cure. But, as a survey by dental experts at ... ,The survey was part of a three day oral ...
... study, it shows little difference in outcome between radical and ... of the breast and the nodes under the armpit// - ... breast cancer. Surgeons are more likely to opt for a ... lump and conserves the breast. ,Researchers at the ...
Cached Medicine News:
... Modular Incubator Chamber has been used worldwide ... conditions for gas mixture and temperature. This ... reliable for in vitro fertilization, HIV isolation, ... environmental contiftions, organ culture and the culturing ...
... range of miniTHERM incubators is available, ensuring ... solution for their specific requirements. miniTHERM incubators ... compact and extremely space saving. Their size ... It is possible to stack up to ...
IR Autoflow Dual Chamber Over-Under Water-Jacketed CO 2 Inc....
3.0% Tryptone, 2.0% Yeast Extract, 1.0% MOPS free acid, 2.0% Glucose....
Medicine Products: